Publications by authors named "Katerina Zemkova"
Article Synopsis
- * Infliximab was associated with higher rates of liver issues, fatigue, and infections, while adalimumab led to more musculoskeletal disorders and infections. Secukinumab patients showed more cardiovascular problems, and etanercept was linked to menstrual disorders.
- * Ustekinumab had the safest profile among the treatments, suggesting that individual risk profiles should be evaluated before starting biologic therapies, and further research is needed to confirm these findings.